Idera Pharmaceuticals, Inc. (IDRA)

NASDAQ: IDRA · IEX Real-Time Price · USD
0.654
-0.046 (-6.56%)
At close: Jan 14, 2022 4:00 PM
0.700
0.046 (7.002%)
After-hours:Jan 14, 2022 7:06 PM EST
Market Cap34.54M
Revenue (ttm)n/a
Net Income (ttm)19.38M
Shares Out52.80M
EPS (ttm)-2.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume238,210
Open0.690
Previous Close0.700
Day's Range0.633 - 0.700
52-Week Range0.510 - 6.140
Beta1.59
AnalystsBuy
Price Target1.00 (+52.9%)
Earnings DateNov 4, 2021

About IDRA

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. an...

IndustryBiotechnology
IPO DateJan 24, 1996
CEOVincent Milano
Employees32
Stock ExchangeNASDAQ
Ticker SymbolIDRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IDRA stock is "Buy." The 12-month stock price forecast is 1.00, which is an increase of 52.88% from the latest price.

Price Target
$1.00
(52.88% upside)
Analyst Consensus: Buy

News

Hot Penny Stocks For 2022 To Buy For Under $2

Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:CLBSFTKGTE
1 week ago - PennyStocks

Idera Pharmaceuticals Announces Tilsotolimod Updates

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synt...

1 month ago - GlobeNewsWire

5 Penny Stocks To Buy According To Analysts & Targets Up To 341%

Analysts are bullish on these penny stocks in 2021. Should you be?

Other symbols:ABUSBFRIRWLKSPI
1 month ago - PennyStocks

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third...

2 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June...

5 months ago - GlobeNewsWire

Why Idera Shares Are Skyrocketing Today

Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares are trading higher by 43% at $1.60 after it was disclosed in a Form 4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock at ...

6 months ago - Benzinga

Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint

Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. The trial assesse...

7 months ago - Benzinga

Idera Pharmaceuticals Announces Corporate Updates

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tilsot...

7 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended Marc...

8 months ago - GlobeNewsWire

Tomslist: The 5 Weirdest Penny Stock Stories of the Week

Even the best penny stocks have their dog days. Here's a celebration of this week's weirdest plays: SNES, IDRA, SOS, TSNPD and HLLPF.

Other symbols:SNESSOS
9 months ago - InvestorPlace

Why Idera Pharmaceuticals Stock Is Crashing Today

The company's experimental cancer drug flopped in a late-stage study.

9 months ago - The Motley Fool

Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade

Shares of Idera Pharmaceuticals Inc. plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatmen...

9 months ago - Market Watch

Why Idera Pharmaceuticals Shares Dropped 62% Lower Today

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet th...

9 months ago - Benzinga

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractor...

– Objective Response Rate Endpoint Not Met – – Objective Response Rate Endpoint Not Met –

9 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?

Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ILLUMINATE-301 Continues on Track for Data Later this Month ILLUMINATE-301 Continues on Track for Data Later this Month

10 months ago - GlobeNewsWire

Idera Pharmaceuticals to Present at Upcoming Conferences

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.

1 year ago - GlobeNewsWire

Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher

Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purc...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

– Protects Method-of-Use in CRC and HNSCC – – Protects Method-of-Use in CRC and HNSCC –

1 year ago - GlobeNewsWire

Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that final data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimo...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for a ...

1 year ago - GlobeNewsWire